医薬品リファレンス
Mavacamten
Mavacamten is a medicine in the class cardiovascular.
- 薬効分類: Cardiovascular
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Cardiovascular
- 一般的な剤形
- カプセル剤
- 既知の相互作用
- 108 (併用禁忌: 20 · 重大: 45 · 中等度: 29 · 軽度: 14)
- 商品名
- 2
- 国・市場
- 2
作用のしくみ
Allosteric, reversible inhibitor selective for cardiac myosin; reduces the number of myosin heads entering power-generating states, lowering systolic and residual diastolic cross-bridge formation, reducing dynamic LVOT obstruction and improving filling pressures.
成人の通常用量（添付文書の要約）
Symptomatic NYHA class II-III obstructive HCM: starting dose 5 mg orally once daily without regard to food; titrate among 2.5 mg, 5 mg, 10 mg or 15 mg once daily; maximum 15 mg once daily
妊娠と授乳
- 妊娠
- Unsafe May cause fetal harm based on animal data; no human data. Effective contraception during treatment and for 4 months after last dose.
- 授乳
- Unknown Presence in milk, effects on infant and milk production are unknown; weigh benefits of breastfeeding against maternal need.
報告されている副作用
- Dizziness
- Syncope
警告（枠囲み警告）
- Reduces LVEF and can cause heart failure from systolic dysfunction. Echocardiographic LVEF assessment required before and during treatment. Do not initiate if LVEF <55%; interrupt if LVEF <50% or heart failure symptoms or worsening clinical status. Strong CYP2C19 inhibitors and moderate to strong CYP2C19 or CYP3A4 inducers are contraindicated. Available only through the CAMZYOS REMS Program.
禁忌
- Concomitant strong CYP2C19 inhibitors
- Concomitant moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers
注意が必要な方
- Heart failure risk higher with serious intercurrent illness or arrhythmia; assess clinical status and LVEF regularly.
- CYP450 interactions may cause heart failure or loss of effectiveness, including with OTC omeprazole, esomeprazole, cimetidine.
- Available only via REMS program; prescribers, patients and pharmacies must be certified/enrolled.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (108)
- Apalutamide + Mavacamten Contraindicated
- Carbamazepine + Mavacamten Contraindicated
- Clarithromycin + Mavacamten Contraindicated
- Dexlansoprazole + Mavacamten Contraindicated
- Efavirenz + Mavacamten Contraindicated
- Enzalutamide + Mavacamten Contraindicated
- Eslicarbazepine + Mavacamten Contraindicated
- Esomeprazole + Mavacamten Contraindicated
- Fluconazole + Mavacamten Contraindicated
- Fluoxetine + Mavacamten Contraindicated
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Mavacamtenの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
WebでPro+を14日間無料でお試し。カード登録不要。
よくある質問
What is Mavacamten used for?
Mavacamten is a medicine in the class cardiovascular.
What side effects have been reported with Mavacamten?
Dizziness, Syncope. Serious warning: Reduces LVEF and can cause heart failure from systolic dysfunction.
Can Mavacamten be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. May cause fetal harm based on animal data; no human data. Effective contraception during treatment and for 4 months after last dose. Breastfeeding: Unknown. Presence in milk, effects on infant and milk production are unknown; weigh benefits of breastfeeding against maternal need.
What does Mavacamten interact with?
MediHelp lists 108 known interactions for Mavacamten. Contraindicated: 20 · Major: 45 · Moderate: 29 · Minor: 14. The most serious include Apalutamide, Carbamazepine, Clarithromycin.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
